28 May 2018 in The Journal of Clinical Endocrinology & Metabolism
Persistent disease after surgery is common in medullary thyroid cancer (MTC) requiring lifelong radiological surveillance. Staging work-up includes imaging of neck, chest, abdomen and bones. A study integrating all sites would be ideal. Despite the established use of 68Ga PET/CT with somatostatin analogs in most neuroendocrine tumors, in MTC its efficacy is controversial. Objective Evaluate the efficacy of 68Ga PET/CT in detecting MTC lesions and evaluate tumor expression of somatostatin receptors (SSTR) associating with 68Ga PET/CT findings. Methods Prospective study evaluating 30 MTC patients; Group 1 (N=16): Biochemical disease and Group 2 (N=14): Metastatic disease. Patients underwent 68Ga PET/CT, bone scan, neck CT and US, CT chest, CT/MRI abdomen, MRI spine. 68Ga PET/CT findings were analyzed by disease site as positive or negative and as concordant or discordant with conventional studies. Sensitivity and specificity were calculated using pathological, cytological analysis or unequivocal identification by standard imaging studies. Immunohistochemical analysis of SSTRs were compared with 68Ga PET/CT findings. Results In both groups 68Ga PET/CT was inferior than currently used imaging studies except for bone scan. In group 2, 68Ga PET/CT sensitivities were 56%, 57% and 9% for detecting neck lymph nodes, lung and liver metastases and 100% for bone metastases, superior than bone scan (44%). Expression of SSTRs, observed in 44% of tumors, was not associated with68Ga DOTATATE uptake. Conclusions 68Ga PET/CT does not provide optimal whole-body imaging as a single procedure in patients with MTC. However, is highly sensitive detecting bone lesions and could substitute bone scan and MRI.
7 May 2018 in Archives of Endocrinology and Metabolism
Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.
25 July 2019 in Lasers in Surgery and Medicine
1 December 2010 in Revista da Sociedade Brasileira de Medicina Tropical
FPFábio Luis Silva Do Prado
Fábio Luis Silva Do Prado
MFMarco Túlio Alves Figueiredo
Marco Túlio Alves Figueiredo
EPEnio Roberto Pietra Pedroso
Enio Roberto Pietra Pedroso
+2
INTRODUCTION: The purpose of this study was to compare respiratory signs and symptoms between patients with and without chest X-ray abnormalities in order to establish the meaning of radiographic findings in pulmonary PCM diagnosis. METHODS: The epidemiological, clinical and radiological lung findings of 44 patients with paracoccidiodomycosis (PCM) were evaluated. Patients were divided into two groups of 23 and 21 individuals according to the presence (group 1) or absence (group 2) of chest X-ray abnormalities, respectively, and their clinical data was analyzed with the aid of statistical tools. RESULTS: As a general rule, patients were rural workers, young adult males and smokers - group 1 and 2, respectively: males (91.3% and 66.7%); mean age (44.4 and 27.9 year-old); smoking (34.7% and 71.4 %); acute/subacute presentation (38.1% and 21.7%); chronic presentation (61.9% and 78.3%). The most frequent respiratory manifestations were - group 1 and 2, respectively: cough (25% and 11.4%) and dyspnea (22.7% and 6.8%). No statistical difference was observed in pulmonary signs and symptoms between patients with or without radiographic abnormalities. The most frequent radiological finding was nodular (23.8%) or nodular-fibrous (19%), bilateral (90.5%) and diffuse infiltrates (85.7%). CONCLUSIONS: Absence of statistical difference in pulmonary signs and symptoms between these two groups of patients with PCM indicates clinical-radiological dissociation. A simplified classification of radiological lung PCM findings is suggested, based on correlation of these data and current literature review.